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Previewshuman colorectal xenografts are treated
with gemcitabine.
The major contributions of Olive et al.
(2009) and Provenzano et al. (2012) are
in demonstrating the importance of the
microenvironment of PDA, and of solid
tumors in general, in determining resis-
tance to drug therapy. The majority of
research on drug resistance has concen-
trated on molecular properties of indi-
vidual cancer cells. Although intrinsic
sensitivity is important, it is only part of
the story—stated simply, if a drug does
not get to some of the tumor cells, they
will not be killed no matter how sensitive
they might be to the drug in cell culture.
More research should focus on strate-
gies that recognize the importance of
the tumor microenvironment and drug
delivery in limiting therapeutic efficacy.
There are several approaches to this
problem, some of which are outlined in
Figure 1. They include strategies to target
the ECMwith enzymes such as PEGPH20
or inhibition of Hedgehog signaling, strat-
egies to decrease drug sequestration in
cells proximal to blood vessels therebyallowing better distribution of drugs to
distal cells, and combination treatment
using ‘‘conventional’’ therapeutics to-
gether with drugs that both diffuse to
and target specifically cells distant from
blood vessels. Promising drugs for the
latter include hypoxia-activated prodrugs
and agents that attack the process of
autophagy, a survival mechanism for
stressed tumor cells (Tre´dan et al., 2007;
Yang et al., 2011).
In summary, the efficiency of systemic
chemotherapy for PDA in particular and
for solid tumors in general is hindered by
poor delivery of drugs to some tumor
regions and by effects of the tumor micro-
environment on drug activity. As Proven-
zano and coworkers show convincingly,
agents that improve drug delivery by
modifying factors relating to the tumor
microenvironment represent an important
future direction for cancer therapy.REFERENCES
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Recent genomic analyses of pediatric glioblastoma, a poorly understood tumor with dismal outcome, have
identified mutations in histone H3 variants that affect critical amino acids in the tail. The findings extend
discoveries of chromatin regulator inactivation and gain-of-function mutations by documenting alteration
of a modifiable histone residue in human cancer.Brain tumors are the most common solid
neoplasms of childhood and the primary
cause of cancer-related deaths in chil-
dren. Although their pathological classifi-
cation is complex, most high-grade brain
tumors in children are categorized as
either embryonal (such as medulloblas-
toma) or glial (such as the diffusely infiltra-tive glioblastoma [GBM]). An anatomical
variant of high-grade glioma, diffuse in-
trinsic pontine glioma (DIPG), is a parti-
cularly vexing clinical challenge given its
location in the neurologically critical brain
stem. Over the past few decades, major
progress has been made in the under-
standing and treatment of children withmedulloblastomas, but little real progress
has been made in the treatment of chil-
dren with malignant diffuse gliomas.
Consistent prognostic estimates have
been difficult to establish, since the
clinical behavior of childhood diffuse
gliomas is not as stereotypical as that of
their more common adult counterpart.1, March 20, 2012 ª2012 Elsevier Inc. 329
Figure 1. Model Depicts Possible Consequences of Histone and ATRX/DAXX Mutations
(Top) Histone H3 mutations may influence transcriptional regulation through loss of H3K27me3, which may impede repression by Polycomb-repressive
complexes PRC1 and PRC2. K27M may also mimic H3K27me1. Structural changes through G34R/V mutation may indirectly affect H3K36 methylation. The
K27M change may also affect distal elements, which are frequently marked by H3K27 acetylation.
(Bottom) Alternatively or in addition, H3F3A and ATRX/DAXX mutants may lead to alternative telomere lengthening.
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PreviewsMoreover, in recent years, it has become
clear that although pediatric diffuse
gliomas appear histologically identical to
adult glioma, they have different under-
lying genetic compositions (Paugh et al.,
2010). For example, whereas IDH1 or
IDH2 mutations are found in the majority
of grade II and III diffuse gliomas in adults
and are thought to constitute early
genetic events, they are rare in pre-
adolescent children (Paugh et al., 2010).
TP53 mutations, a cardinal feature of
diffuse astrocytic gliomas in adults, are
far less common in diffuse gliomas in
the first few years of life (Pollack et al.,
2001), and combined loss of chromo-
some arms 1p and 19q, the classic
genetic finding in diffuse oligodendroglio-
mas in adults, is exceedingly rare in pedi-
atric oligodendrogliomas (Kreiger et al.,
2005). Although it has been clear that pedi-
atric diffuse gliomas are clinically and
genetically different from their adult coun-
terparts, no distinct genetic marker and
key pathogenic mechanism has yet been
discovered.330 Cancer Cell 21, March 20, 2012 ª2012 ETwo independent studies used whole-
genome or whole-exome sequencing to
interrogate the cancer genome of pedi-
atric diffuse glioma (Schwartzentruber
et al., 2012; Wu et al., 2012). In an ex-
tensive survey, Schwartzentruber et al.
(2012) performed initial whole-exome
sequencing of 48 pediatric GBMs, and 6
matched normal samples and discovered
recurrent mutations in the H3F3A gene,
encoding histone H3.3, in 31% of cases.
These mutations were highly specific and
comprised either K27M (9 of 48 cases),
G34R (5 of 48 cases) or G34V (1 case).
Interestingly, in an additional cohort of
784 adult and pediatric gliomas, H3F3A
mutations were found in only 3% of adult
GBMs but in 32% of pediatric GBMs and
18%ofpediatric anaplastic astrocytomas.
Wu et al. (2012) foundH3F3AK27Mmuta-
tions through whole-genome sequencing
of 7 DIPGs and targeted sequencing of
43 additional DIPGs and 36 pediatric
GBMs. Notably, K27M mutations were
also found in the canonical histone H3.1
(HIST1H3B) in 18% of DIPGs. All histonelsevier Inc.alterations identified in the two studies
are heterozygous, suggesting that these
are gain-of-function mutations.
Histone H3.3 is deposited at active
gene loci in the genome as well as at peri-
centromeres and telomeres. Unlike its
canonical counterpart H3.1, H3.3 is incor-
porated into chromatin independently of
the cell replication cycle (Talbert and
Henikoff, 2010). The two mutations found
in the two studies are located in the
histone tail that is subject to extensive
post-translational modification. In partic-
ular, the K27M mutation will block two
widely studiedmodifications: K27methyl-
ation, associated with Polycomb-medi-
ated gene repression (Simon and King-
ston, 2009), and K27 acetylation, present
at active promoters and enhancers
(Zhou et al., 2011). Although H3G34 is
not itself subject to post-translational
modification, it resides in close proximity
to a lysine at position 36 (H3K36), whose
methylation status is associatedwith tran-
scriptional elongation (Zhou et al., 2011).
In support of an indirect effect on
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PreviewsH3K36, Schwartzentruber et al. (2012)
show that H3K36 methylation levels are
increased in a tumor with G34R mutation.
In addition, expression profiling of K27M
and G34R/V mutant GBMs demonstrated
differences in expression patterns of
neural development genes, likely reflect-
ing different effects of the two mutations
on gene regulation.
Although H3.3 mutations conceivably
affectgene regulatory functions, theselec-
tive advantage in pediatricGBMmayactu-
ally relate to telomeremaintenance and/or
heterochromatin stability. Deposition of
H3.3 within these genomic contexts is
mediated by the ATRX-DAXX complex
(Goldberg et al., 2010). Schwartzentruber
et al. (2012) identified recurrent mutations
in ATRX (14/48 cases) and its binding
partner DAXX (2/48 cases). Overall, 21 of
48 (44%) pediatric GBMs had mutations
in H3F3A, ATRX, or DAXX. Mutation of
the ATRX-DAXX complex and either H3.3
tail mutation correlated with loss of ATRX
expression in a pediatric GBM tissue array
and an alternative lengthening of telo-
meres phenotype in GBM. Interestingly,
although IDH1 mutations were identified
in 4 of 48 pediatric GBM, they were mutu-
ally exclusive with H3F3A/ATRX/DAXX
mutations in this cohort.
Links between chromatin and cancer
were initially drawn by oncogenic fusions
containing chromatin proteins and by theanti-proliferative properties of chemical
inhibitors of histone deacetylases (Baylin
and Jones, 2011). These have been
strengthened recently as an increasing
number of whole-genome and exome
cancer sequencing studies have identi-
fied prevalent mutations in histone modi-
fying enzymes, nucleosome remodelers,
and other regulatory proteins in chro-
matin. Although such findings are sugges-
tive of direct roles for histone modifica-
tions, they fall short of definitive proof
given that modifying enzymes also have
nonhistone targets and frequently reside
within large complexes with multi-faceted
functions. Thus, the studies now pre-
sented by Schwartzentruber et al. (2012)
and Wu et al. (2012) extend our under-
standing of how defects in chromatin
contribute to cancer fitness by providing
the first evidence of somatic mutations
directly affecting a modifiable residue in
histone proteins (Figure 1). Further study
is essential to understand the mecha-
nisms by which these and other alter-
ations to the chromatin machinery con-
tribute to malignant transformation and
how they may be exploited for improved
diagnosis and therapy.ACKNOWLEDGMENTS
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